Quest Diagnostics Declares Quarterly Cash Dividend of $0.80 per Share

Dyadic International reported Q2 2025 earnings with GAAP revenue of $967,000, a YoY increase from Q2 2024. The company completed a leadership transformation, rebranding, and shifted from its historical R&D focus to prioritize predictable, scalable revenue generation across three non-therapeutic business segments. Both the C1 and Dapivis protein expression platforms have been adapted for high-yield, animal-free protein production targeting cell culture media, diagnostics, and industrial applications. The company narrowed its Q2 loss and expects to keep operating expenses flat or lower for the remainder of 2025.

Dyadic International, a biotechnology company, reported its Q2 2025 earnings on August 13, 2025, showing a year-over-year (YoY) increase in revenue to $967,000. The company's earnings call highlighted a strategic shift from a research and development (R&D) focus to prioritizing predictable, scalable revenue generation across three non-therapeutic business segments. This transformation includes the successful completion of a leadership transformation and rebranding to Dyadic Applied Biosolutions [1].

The company's proprietary C1 and Dapivis protein expression platforms have been adapted for high-yield, animal-free protein production, targeting applications in cell culture media, diagnostics, and industrial sectors. Dyadic's Q2 2025 operating loss narrowed to $1,729,000, an improvement from $2,043,000 in the same period last year. The company expects operating expenses to remain flat or decline in the second half of 2025, depending on revenue outcomes [1].

Dyadic's Q2 2025 revenue was driven by milestone payments for enzyme development and grants from the Gates Foundation and CEPI. The company's research and development expenses totaled $629,000 for the quarter, reflecting growth in internal product development initiatives. General and administrative expenses were $1,437,000 for Q2 2025, down from $1,608,000 in Q2 2024 [1].

The company's liquidity position improved, with cash, equivalents, restricted cash, and investment-grade securities totaling $7,300,000 as of June 30, 2025. Dyadic also completed a $5,300,000 equity raise on August 1, 2025, with proceeds designated for product development, sales, and general corporate purposes. The company's product pipeline includes recombinant human albumin, transferrin, and fibroblast growth factors, with launches expected in 2025 and 2026 [1].

Dyadic's strategic priorities focus on high-demand non-therapeutic markets, where its platforms enable rapid, cost-effective, and scalable protein production. The company remains committed to addressing the growing global demand for sustainable precision-engineered proteins that power progress across various industries [1].

References:
[1] https://www.fool.com/earnings/call-transcripts/2025/08/13/dyadic-dyai-q2-2025-earnings-call-transcript/